All In Biotech

Drug Trial Radar · NCT06720233

Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis

A Phase III, Multicenter, Open-label, Single-arm Clinical Study to Evaluate the Efficacy and Safety of SAL-0951 Tablets in the Treatment of Renal Anemia in Patients With Chronic Kidney Disease Receiving Maintenance Peritoneal Dialysis

Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

37

Actual

Start

Feb 22, 2002

Primary completion

Oct 18, 2024

Study completion Oct 28, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in Chinese patients receiving peritoneal dialysis with chronic kidney disease and anemia

Conditions

  • Anemia

Interventions

  • SAL-0951 tabletsDrug

    initial phase:4mg QD subsequent phase:1mg~8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Hb level and 95% CI during the evaluation period after the 24-week treatment period or at the end of treatmentTime frame: at Weeks 20, 22, and 24 [or end-of-treatment date]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.